Aytu Biopharma (AYTU) Net Income towards Common Stockholders (2010 - 2026)

Aytu Biopharma (AYTU) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$5.6 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 240.66% year-over-year to -$5.6 million in Q1 2026; TTM through Mar 2026 was -$30.7 million, a 613.99% decrease from a year earlier, with the FY2025 full-year figure at -$10.2 million, up 11.24% from the prior year.
• Net Income towards Common Stockholders was -$5.6 million for Q1 2026 at Aytu Biopharma, up from -$10.6 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $7.0 million in Q2 2022 and troughed at -$53.3 million in Q1 2022.
• A 5-year average of -$5.6 million and a median of -$701000.0 in 2022 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders soared 435.42% in 2024 and plunged 5468.92% in 2025, its largest moves.
• Over 5 years, Net Income towards Common Stockholders stood at -$6.7 million in 2022, then surged by 96.41% to -$240000.0 in 2023, then soared by 435.42% to $805000.0 in 2024, then slumped by 1414.78% to -$10.6 million in 2025, then surged by 46.92% to -$5.6 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$5.6 million (Q1 2026), -$10.6 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.